[{"address1": "Paasheuvelweg 25", "city": "Amsterdam", "zip": "1105 BP", "country": "Netherlands", "phone": "31 20 240 6000", "website": "https://www.uniqure.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases in the United States. The company offers HEMGENIX that allows people living with hemophilia B to produce factor IX, which can lower the risk of bleeding. Its lead product candidate is AMT-130, a gene therapy candidate, which is in Phase I/II clinical study for the treatment of Huntington's disease. The company also develops AMT-260, which is in Phase I/IIa clinical trial for the treatment of mesial temporal lobe epilepsy; AMT-162, which is in Phase I/IIa clinical trial to treat superoxide dismutase enzyme-amyotrophic lateral sclerosis; and AMT-191, an investigational gene therapy candidate which is in phase I/IIa clinical trial for the treatment of fabry disease. It has a licensing agreement with Apic Bio to develop, manufacture, and commercialize intrathecally administered investigational gene therapy for ALS caused by mutations in SOD-1; and development and commercial supply agreement with CLS Bhering. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.", "fullTimeEmployees": 209, "companyOfficers": [{"maxAge": 1, "name": "Mr. Christian  Klemt", "age": 51, "title": "CFO, Principal Financial Officer & GM of Amsterdam Site", "yearBorn": 1973, "fiscalYear": 2024, "totalPay": 679793, "exercisedValue": 0, "unexercisedValue": 282015}, {"maxAge": 1, "name": "Dr. Jeannette  Potts J.D., Ph.D.", "age": 62, "title": "Chief Legal & Compliance Officer and Corporate Secretary", "yearBorn": 1962, "fiscalYear": 2024, "totalPay": 738547, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Walid  Abi-Saab M.D.", "age": 59, "title": "Chief Medical Officer", "yearBorn": 1965, "fiscalYear": 2024, "totalPay": 946132, "exercisedValue": 0, "unexercisedValue": 268795}, {"maxAge": 1, "name": "Prof. Hugo  Katus", "title": "Chairman of Scientific Advisory Board and Managing Director of UniQure-Germany", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Amin  Abujoub Ph.D.", "title": "Chief Technical Operations Officer", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Richard  Porter Ph.D.", "age": 56, "title": "Chief Business & Scientific Officer", "yearBorn": 1968, "fiscalYear": 2024, "totalPay": 732169, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Tamara  Tugal Ph.D., MBA", "title": "Business Development Director", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Erin  Boyer", "title": "Chief People & Culture Officer", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 8, "boardRisk": 3, "compensationRisk": 4, "shareHolderRightsRisk": 1, "overallRisk": 2, "governanceEpochDate": 1748736000, "compensationAsOfEpochDate": 1735603200, "executiveTeam": [], "maxAge": 86400, "priceHint": 2, "previousClose": 15.99, "open": 15.46, "dayLow": 15.06, "dayHigh": 16.0, "regularMarketPreviousClose": 15.99, "regularMarketOpen": 15.46, "regularMarketDayLow": 15.06, "regularMarketDayHigh": 16.0, "payoutRatio": 0.0, "beta": 0.09, "forwardPE": -5.013072, "volume": 738605, "regularMarketVolume": 738605, "averageVolume": 1802819, "averageVolume10days": 1209900, "averageDailyVolume10Day": 1209900, "bid": 15.19, "ask": 15.46, "bidSize": 10, "askSize": 10, "marketCap": 839841984, "fiftyTwoWeekLow": 3.73, "fiftyTwoWeekHigh": 19.18, "priceToSalesTrailing12Months": 41.574276, "fiftyDayAverage": 13.3935, "twoHundredDayAverage": 11.07685, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "tradeable": false, "enterpriseValue": 979273472, "profitMargins": 0.0, "floatShares": 35566265, "sharesOutstanding": 54748500, "sharesShort": 7454081, "sharesShortPriorMonth": 5544310, "sharesShortPreviousMonthDate": 1745971200, "dateShortInterest": 1748563200, "sharesPercentSharesOut": 0.1362, "heldPercentInsiders": 0.08285, "heldPercentInstitutions": 0.92061996, "shortRatio": 3.72, "shortPercentOfFloat": 0.138, "impliedSharesOutstanding": 54748500, "bookValue": 0.616, "priceToBook": 24.902597, "lastFiscalYearEnd": 1735603200, "nextFiscalYearEnd": 1767139200, "mostRecentQuarter": 1743379200, "netIncomeToCommon": -217575008, "trailingEps": -4.38, "forwardEps": -3.06, "enterpriseToRevenue": 48.476, "enterpriseToEbitda": -6.214, "52WeekChange": 2.270789, "SandP52WeekChange": 0.09203708, "quoteType": "EQUITY", "currentPrice": 15.34, "targetHighPrice": 70.72799, "targetLowPrice": 13.333717, "targetMeanPrice": 35.804043, "targetMedianPrice": 30.311995, "recommendationMean": 1.46154, "recommendationKey": "strong_buy", "numberOfAnalystOpinions": 11, "totalCash": 409011008, "totalCashPerShare": 7.471, "ebitda": -157584000, "totalDebt": 512856000, "quickRatio": 11.334, "currentRatio": 11.992, "totalRevenue": 20201000, "debtToEquity": 1522.46, "revenuePerShare": 0.405, "returnOnAssets": -0.15642, "returnOnEquity": -2.4116, "grossProfits": -125126000, "freeCashflow": -122885504, "operatingCashflow": -166252992, "revenueGrowth": -0.815, "grossMargins": 0.0, "ebitdaMargins": 0.0, "operatingMargins": -28.15252, "financialCurrency": "USD", "symbol": "QURE", "language": "en-US", "region": "US", "typeDisp": "Equity", "quoteSourceName": "Delayed Quote", "triggerable": true, "customPriceAlertConfidence": "HIGH", "hasPrePostMarketData": true, "firstTradeDateMilliseconds": 1391610600000, "epsTrailingTwelveMonths": -4.38, "epsForward": -3.06, "epsCurrentYear": -2.9997, "priceEpsCurrentYear": -5.113845, "fiftyDayAverageChange": 1.9464998, "fiftyDayAverageChangePercent": 0.14533168, "twoHundredDayAverageChange": 4.26315, "twoHundredDayAverageChangePercent": 0.38487026, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "averageAnalystRating": "1.5 - Strong Buy", "cryptoTradeable": false, "marketState": "CLOSED", "postMarketChangePercent": 1.4341608, "postMarketPrice": 15.56, "postMarketChange": 0.22000027, "regularMarketChange": -0.65, "regularMarketDayRange": "15.06 - 16.0", "fullExchangeName": "NasdaqGS", "averageDailyVolume3Month": 1802819, "fiftyTwoWeekLowChange": 11.610001, "fiftyTwoWeekLowChangePercent": 3.1126006, "fiftyTwoWeekRange": "3.73 - 19.18", "fiftyTwoWeekHighChange": -3.8400002, "fiftyTwoWeekHighChangePercent": -0.20020856, "fiftyTwoWeekChangePercent": 227.07889, "earningsTimestamp": 1746788700, "earningsTimestampStart": 1753959900, "earningsTimestampEnd": 1754391900, "earningsCallTimestampStart": 1746793800, "earningsCallTimestampEnd": 1746793800, "isEarningsDateEstimate": true, "shortName": "uniQure N.V.", "longName": "uniQure N.V.", "corporateActions": [], "postMarketTime": 1749857557, "regularMarketTime": 1749844801, "exchange": "NMS", "messageBoardId": "finmb_171029664", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EDT", "gmtOffSetMilliseconds": -14400000, "market": "us_market", "esgPopulated": false, "regularMarketChangePercent": -4.06504, "regularMarketPrice": 15.34, "displayName": "uniQure", "trailingPegRatio": null, "__fetch_time": "2025-06-14"}]